Cecilia Y Arana Yi

9PUBLICATIONS
30CO-AUTHORS
Predictive and prognostic markersGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Nov 29, 2025
Predictors of Symptom Scores in Myeloproliferative Neoplasms: A Real-World Retrospective Cohort Study.

Muhammad Ali Khan, Syed Arsalan Ahmed Naqvi, John K Camoriano

|Jul 03, 2025
Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System.

Fnu Aperna, Maymona G Abdelmagid, Mahesh Kumar

|Dec 13, 2024
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.

Naseema Gangat, Azeem Elbeih, Nour Ghosoun

|Dec 15, 2023
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.

Omer Karrar, Maymona Abdelmagid, Masooma Rana

|Dec 10, 2023
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.

Naseema Gangat, Omer Karrar, Moazah Iftikhar

|Sep 04, 2023
Patients with telomere biology disorders show context specific somatic mosaic states with high frequency of U2AF1 variants.

Alejandro Ferrer, Terra Lasho, Jenna A Fernandez

Pageof 2

Frequent Collaborators

6 joint publications

Mrinal S Patnaik

5 joint publications

Animesh Pardanani

5 joint publications

Talha Badar

5 joint publications

Abhishek Mangaonkar